Teza Capital Management LLC Buys 429 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Teza Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 49.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,294 shares of the biopharmaceutical company's stock after acquiring an additional 429 shares during the quarter. Teza Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $922,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Willner & Heller LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after buying an additional 15 shares during the last quarter. OLD Second National Bank of Aurora lifted its position in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after acquiring an additional 15 shares in the last quarter. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. TD Private Client Wealth LLC lifted its position in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 18 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $10.17 during trading on Wednesday, reaching $604.62. The company's stock had a trading volume of 1,089,118 shares, compared to its average volume of 795,612. Regeneron Pharmaceuticals, Inc. has a 1 year low of $520.50 and a 1 year high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $65.28 billion, a P/E ratio of 15.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company's fifty day moving average is $595.54 and its 200-day moving average is $679.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the previous year, the company posted $9.55 EPS. The company's quarterly revenue was down 3.7% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on REGN. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. Finally, Guggenheim decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.